ARDX
What one share of Ardelyx holds
Pharmaceutical Preparations
We are a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. We currently market two therapies from the active ingredient tenapanor, a sodium/hydrogen exchanger (NHE3) inhibitor that was discovered and developed by Ardelyx.
Ardelyx’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $1.84 |
|---|---|
| Profit | −$0.23 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.07 |
| Cash and investments | $0.39 |
| Debt | $1.01 |
| Book value | $0.60 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2012 | $6.26 | −$11.32 | $0.15 | $25.29 | — | −$66.42 |
| 2013 | $25.65 | −$5.82 | $0.25 | $1.36 | — | −$51.80 |
| 2014 | $3.09 | −$0.31 | $0.18 | $1.13 | — | $3.26 |
| 2015 | $1.05 | −$1.29 | $0.15 | −$3.29 | — | $4.19 |
| 2016 | — | −$2.80 | $0.12 | −$2.43 | — | $4.08 |
| 2017 | $0.89 | −$1.36 | $0.05 | −$1.42 | — | $2.93 |
| 2018 | $0.05 | −$1.62 | $0.01 | −$1.26 | — | $1.85 |
| 2019 | $0.08 | −$1.47 | $0.01 | −$1.19 | — | $2.10 |
| 2020 | $0.08 | −$1.05 | $0.00 | −$0.91 | — | $1.35 |
| 2021 | $0.10 | −$1.52 | $0.02 | −$1.48 | — | $0.63 |
| 2022 | $0.33 | −$0.42 | $0.00 | −$0.44 | — | $0.50 |
| 2023 | $0.57 | −$0.30 | $0.00 | −$0.41 | — | $0.72 |
| 2024 | $1.42 | −$0.17 | $0.00 | −$0.19 | — | $0.73 |
| 2025 | $1.69 | −$0.26 | $0.01 | −$0.18 | — | $0.68 |